Brainsway

Bull case

BrainsWay is well positioned because its Deep TMS platform is generating expanding clinical validation and tangible commercial pull, including a multi-unit order through Inland Psychiatric Medical Group and a growing installed-base model that supports recurring, high-margin revenue. The evidence base is strengthening across multiple indications, with a 70% relative reduction in suicidal ideation over six weeks in 89 MDD patients, an 83.3% response rate and 50% remission rate in 12 patients with MDD and early-stage Alzheimer's, and an 83.5% PTSD symptom response rate in 462 real-world patients across 11 clinical sites. Combined with a new FDA clearance application for comorbid PTSD/MDD, ongoing AUD enrollment, and planned feasibility studies in dementia and Parkinson's disease, the company appears to have multiple pathways to sustained growth and broader regulatory expansion.

Bear case

• BrainsWay is benefiting from broader U.S. reimbursement, with over 70M covered lives now accessible under policies covering SWIFT, which should support adoption of its Deep TMS platform.
• However, the investment case remains fragile because the valuation depends on a 5.6x sales multiple applied to $78.5M in forward 12-month revenue, while execution risks include slower-than-projected system uptake, limited expansion into other indications, and possible long-term dilution.
• Its ARR-driven model and ~$62.1M in cash as of mid-2026 offer some support, but inconsistent commercial execution, pricing pressure, regulatory delays, and higher operating expenses could prevent sustainable profitability and undermine downside protection.